医学
PI3K/AKT/mTOR通路
再灌注损伤
肠缺血
蛋白激酶B
肺
药理学
缺血
大黄素
信号转导
内科学
细胞生物学
生物化学
化学
生物
作者
Meng Chen,Tuo Ji,Yin-Yin Liu,Wanli Liu,Xue-Tao Yan,Hai-Xing Jiang,Zongze Zhang,Xianghu He
出处
期刊:Surgery
[Elsevier]
日期:2024-05-28
卷期号:176 (2): 499-510
被引量:1
标识
DOI:10.1016/j.surg.2024.04.006
摘要
Background Emodin, a natural anthraquinone derivative found in various Chinese medicinal herbs, has been proved to be an effective therapeutic agent in the treatment of many diseases. However, its effect on lung injury after intestinal ischemia/reperfusion injury remains unknown. This research was designed to investigate whether emodin protects against intestinal ischemia/reperfusion-induced lung injury and to elucidate the underlying molecular mechanisms in vivo and in vitro. Methods Intestinal ischemia/reperfusion injury was induced by occluding the superior mesenteric artery in mice, and mouse lung epithelial-12 cells were subjected to oxygen-glucose deprivation and reoxygenation to establish an in vitro model. Results Our data indicated that emodin treatment reduced intestinal ischemia/reperfusion-induced oxidative stress, inflammation and apoptosis in lung tissues and alleviated lung injury. However, the protective effects of emodin on intestinal ischemia/reperfusion-induced lung injury were reversed by the protein kinase B inhibitor triciribine or the heme oxygenase-1 inhibitor tin protoporphyrin IX. The protein kinase inhibitor triciribine also downregulated the expression of heme oxygenase-1. Conclusion In conclusion, our data suggest that emodin treatment protects against intestinal ischemia/reperfusion-induced lung injury by enhancing heme oxygenase-1 expression via activation of the PI3K/protein kinase pathway. Emodin may act as a potential therapeutic agent for the prevention and treatment of lung injury induced by intestinal ischemia/reperfusion.
科研通智能强力驱动
Strongly Powered by AbleSci AI